UFP Technologies has developed a customizable insulated shipping container for its BioShell Suspension Pack for protecting single-use biopharmaceutical bags during storage, handling, and shipping.
Tuna Sava, Manager of BioPharm Products, tells PMP News that BioShell consists of a polycarbonate shell and TPU suspension film. Introduced in 2011, "Bioshell accommodates any size bag from 50 mL sample bags to 20 L," Sava reports, adding that the company is "currently working on larger ones."
ABBOTT PARK, Ill.,
In 1964, Formost Packaging Machines took the radical step of packaging bread in polyethylene bags instead of traditional waxed paper despite resistance from the food industry. This year, as Formost celebrates its 50th anniversary, its role in the medical packaging industry is fairly unique as well. The company’s flow-wrap form-fill-seal (FFS) equipment offers an alternative to traditional thermorming FFS machines.
The 2014 awards program for Innovation in Plastics Recycling is now open for nominations. Organized by the Plastics Division of the American Chemistry Council (ACC), the program honors North American companies, individuals, and government bodies (including schools) for developing new technologies, products, and initiatives using post-consumer recycled plastics, ACC reports in a news release.
Experiencing tremendous growth upwards of 40%, nutritional supplement formulator and supplier Jarrow Formulas Inc. (JFI) is adding to its already extensive line up of products for bone and joint health, gastrointestinal and cardiovascular health, sports nutrition, and others. “We are just shy of 400 SKUs and growing, adding 15 to 20 new products per year,” says Juliun Brabon, president of the Santa Fe Springs, CA-based company.
Hundreds of millions of folding cartons from DISC marked with ADNAS SigNature DNA exemplify industry partnerships in combatting counterfeiting of products in markets where authentication is crucial.
Noven Pharmaceuticals, Inc. announced Sept. 24 that the U.S. Food and Drug Administration has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. With this new approval, women who are using Minivelle to treat their VMS symptoms have the benefit of also helping to prevent osteoporosis.
From IBISWorld Global Pharmaceuticals analyst Sarah Turk:
Merck will acquire all of the outstanding shares of Sigma-Aldrich for $140 per share in cash. The agreed price represents a 37% premium to the latest closing price of $102.37 on September 19, 2014, and a 36% premium to the one-month average closing price. The transaction is expected to be immediately accretive to Merck's EPS pre and EBITDA margin. Merck expects to achieve annual synergies of approximately ?260 million (approximately $340 million), which should be fully realized within three years after closing.